PEAK6 Investments L.P. Purchases Shares of 67,652 NxStage Medical, Inc. (NXTM)

PEAK6 Investments L.P. purchased a new stake in NxStage Medical, Inc. (NASDAQ:NXTM) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 67,652 shares of the medical device company’s stock, valued at approximately $1,867,000. PEAK6 Investments L.P. owned about 0.10% of NxStage Medical as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the business. Suntrust Banks Inc. boosted its stake in shares of NxStage Medical by 2.3% during the 2nd quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after acquiring an additional 209 shares in the last quarter. Amalgamated Bank boosted its stake in shares of NxStage Medical by 7.1% during the 2nd quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after acquiring an additional 553 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of NxStage Medical by 3.5% during the 2nd quarter. Legal & General Group Plc now owns 25,349 shares of the medical device company’s stock worth $630,000 after acquiring an additional 856 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of NxStage Medical by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 50,336 shares of the medical device company’s stock worth $1,262,000 after acquiring an additional 1,059 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of NxStage Medical by 4.1% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 33,866 shares of the medical device company’s stock worth $849,000 after acquiring an additional 1,334 shares in the last quarter. 85.68% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, August 10th. BTIG Research lowered shares of NxStage Medical from a “buy” rating to a “neutral” rating in a research note on Friday, August 11th. Stephens lowered shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $33.00 to $30.00 in a research note on Wednesday, August 9th. Leerink Swann lowered shares of NxStage Medical from an “outperform” rating to a “market perform” rating and raised their price target for the company from $28.00 to $30.00 in a research note on Tuesday, August 22nd. Finally, Northland Securities reaffirmed a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a research note on Wednesday, November 8th. Two analysts have rated the stock with a sell rating and eight have issued a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $30.25.

NxStage Medical, Inc. (NXTM) opened at $25.62 on Thursday. NxStage Medical, Inc. has a 12 month low of $20.45 and a 12 month high of $30.80.

In other NxStage Medical news, SVP Matthew W. Towse sold 4,300 shares of the stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $27.27, for a total value of $117,261.00. Following the completion of the sale, the senior vice president now owns 28,721 shares in the company, valued at approximately $783,221.67. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction dated Friday, October 20th. The shares were sold at an average price of $27.50, for a total transaction of $96,250.00. Following the completion of the sale, the senior vice president now owns 15,270 shares of the company’s stock, valued at approximately $419,925. The disclosure for this sale can be found here. Insiders sold a total of 12,300 shares of company stock worth $331,126 over the last ninety days. 4.70% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This news story was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2017/12/07/peak6-investments-l-p-purchases-shares-of-67652-nxstage-medical-inc-nxtm.html.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply